Cardiovascular

Latest News

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease
Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

June 3rd 2025

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com
CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

May 23rd 2025

AJMC
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

May 16th 2025

Doctor taking child's blood pressure | Image credit: romaset – stock.adobe.com
3 Maternal Risk Factors Linked to Elevated Offspring Blood Pressure

May 14th 2025

Nurse using stethoscope on older patient | Image credit: InsideCreativeHouse – stock.adobe.com
Is Frailty Index the Most Accurate Predictor of CVD?

May 9th 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Continuing Medical Education
View All
June 9th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
June 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 9th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

Guidelines-momius-stock.adobe.com
February 28th 2025

AHA, ACC Update Guidelines for Acute Coronary Syndrome Management

Giuliana Grossi
The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic shock management, and secondary prevention.
Aortic Stenosis remains a serious, worldwide cardiovascular complication | image credit: Pumpala - stock.adobe.come
February 19th 2025

Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis

Kyle Munz
This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.
Antoine Keller, MD
February 18th 2025

HeartSense's Mission to Reveal, Combat Hidden CV Burdens in Underserved Communities

Kyle Munz Antoine Keller, MD, FACC, FACS
Antoine Keller, MD, founded HeartSense with the purpose of uncovering and addressing the cardiovascular needs of rural, often underserved communities.
Heart health. | Image Credit: udra11 - stock.adobe.com
February 14th 2025

5 Things That Impact Heart Health

Cameron Santoro
To maintain a healthy heart, researchers say people should focus on diet and exercise, limit alcohol, manage stress, get enough sleep, and more.
Christian Ruff, MD
February 11th 2025

Abelacimab Shows Potential to Shift the Standard of Care in AFib

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
Christian Ruff, MD
February 6th 2025

Dr Ruff Explores Mitigating Surgical Bleeding in AFib With Abelacimab

Kyle Munz Christian Ruff, MD
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
Conceptualizing reduced cost and increased value | image credit: patpitchaya - stock.adobe.com
February 3rd 2025

Polypill Treatment: A Clinically Effective and Cost-Saving Strategy for CVD Management

Kyle Munz
A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.
FDA approval | image credit: Aquir - stock.adobe.com
January 28th 2025

FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD

Kyle Munz
The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.
Glass of sugar cubes | Image Credit: © grzejnik1981-stock.adobe.com
January 28th 2025

Curbing Sugary Beverages for Health and Economic Gains

Maggie L. Shaw
According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 diabetes, heart disease, nonalcoholic liver disease, and gout.
Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com
January 22nd 2025

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
Breast cancer awareness graphic | image credit: ST.art - stock.adobe.com
January 15th 2025

Breast Cancer Stage May Influence Risk of Prevalent CVD

Kyle Munz
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
heart of pills-Denira-stock.adobe.com
January 14th 2025

Economic Data Show Cost-Effectiveness of Statin, Antihypertensive Polypill for CVD in Low-Income Populations

Giuliana Grossi
The health equity impact of the polypill is significant; by effectively controlling cardiovascular disease (CVD) risk factors in populations with limited health care access, there's potential to reduce income- and race-related health disparities.
Coffee | Image credit: dimakp - stock.adobe.com
January 9th 2025

Lower Risk of Cardiovascular Disease Mortality Associated With Morning Coffee

Julia Bonavitacola
Americans who drank coffee in the morning had a lower overall mortality compared with those who drank coffee later in the day.
Keith Ferdinand, MD, professor of medicine and the Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine
January 7th 2025

CKM Treatment Involves a Team-Based Approach, Says Dr Keith Ferdinand

Pearl Steinzor
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, continues his discussion on treatment approaches for patients with cardiovascular-kidney-metabolic (CKM) syndrome.
Cardiovascular top 5 of 2024 | Image Credit: Venngage
December 25th 2024

Top 5 Most-Read Cardiovascular Content of 2024

Brooke McCormick
This year's top 5 most-read cardiovascular articles explored topics ranging from FDA approvals to the risks associated with the sugar alcohol xylitol and beyond.
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
December 20th 2024

Tackling CKM Syndrome as a Holistic Approach to a Growing Health Crisis

Pearl Steinzor
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the interconnected condition of cardiovascular-kidney-metabolic (CKM) syndrome, which includes obesity, diabetes, chronic kidney disease, and cardiovascular disease.
AHA 2024 Highlights
December 20th 2024

ICYMI: AHA 2024 Scientific Session Highlights

Brooke McCormick
Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights and highlighted promising treatments.
Heart pulse, beat concept in atrial fibrillation | image credit: martialred - stock.adobe.com
December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz
Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.
ASCVD | Image credit: Zhanna - stock.adobe.com
December 17th 2024

Low Lp(a) Testing in ASCVD: Higher Levels in Black and Female Patients

Pearl Steinzor
Study identifies underutilization of testing, with disparities by race and sex.
AJMC
December 11th 2024

Impact of Delayed Adoption of Novel Atrial Fibrillation Treatments

Jaehong Kim, PhD Jeremy Nighohossian, PhD Anastasia G. Daifotis, MD Jinghua He, PhD Jason Shafrin, PhD
Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost.
Highlights from ASPC Congress 2024 | Image Credit: venngage.com
December 9th 2024

ICYMI: Highlights From ASPC Congress 2024

Brooke McCormick
The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, as well as coverage on multiple areas of cardiovascular medicine.
EKG heartbeat line | Image Credit: Jiva Core - stock.adobe.com
December 6th 2024

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Brooke McCormick
Data presented at the 2024 American Heart Association (AHA) Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Atrial fibrillation | Image credit: ibreakstock - stock.adobe.com
December 5th 2024

Lifestyle Changes Ease AFib Symptoms but Don't Lower Burden vs Standard Care

Pearl Steinzor
Metformin and lifestyle changes show no significant impact on atrial fibrillation (AFib) burden or progression compared with standard care.
FDA headquarters | Image Credit: Grandbrothers - stock.adobe.com
November 25th 2024

FDA Approves Acoramidis for ATTR-CM

Patrick Campbell
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete stabilization of transthyretin (TTR).
Cardiovascular health | Image Credit: BillionPhotos.com - stock.adobe.com
November 25th 2024

Unfavorable Health-Related Social Needs Associated With Lower Cardiovascular Health Scores

Brooke McCormick
Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.
Heart examination | Image credit: Ngampol - stock.adobe.com
November 20th 2024

Elevated Stress Hyperglycemia Ratio Linked to Higher All-Cause Mortality After Cardiovascular Events

Pearl Steinzor
Evidence highlights the predictive value of the stress hyperglycemia ratio for mortality risk in patients with acute myocardial infarction, ischemic stroke, and acute heart failure.
Smoking health risk | Image credit: sorapop - stock.adobe.com
November 15th 2024

How Smoking Cessation Affects Cardiovascular Disease Risk Over Time

Pearl Steinzor
New study findings reveal that the risk of cardiovascular disease among light ex-smokers aligns quickly with never-smokers, while heavy ex-smokers may take over 25 years to reach the same level.
Stressed female employee | Image Credit: Charlie's - stock.adobe.com
November 6th 2024

Work-Related Stress Linked to Poor Cardiovascular Health

Brooke McCormick
A new study has linked work-related stress to poorer cardiovascular health, highlighting the need for workplace wellness programs to reduce the risk of cardiovascular disease.
Doctor holding heart_Pana Studio - stock.adobe.com.jpeg
October 24th 2024

Evaluating the American Heart Association’s PREVENT Equations: Enhancing CVD Risk Prediction

Pearl Steinzor
A new study assesses the prognostic accuracy of Predicting Risk of CVD EVENTs (PREVENT) equations for predicting cardiovascular disease (CVD) mortality in the US population.
Viet Le, PA-C, Intermountain Health
October 19th 2024

Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery

Kyle Munz
Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.
<12345678
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo